2,4-二甲氧基苯基丙酮 | 831-29-8

• 物质功能分类: 香精与香料 - 合成香料 - 酮类香料
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二甲氧基苯基丙酮
• 中文别名: 2,4-二甲氧基苯丙酮；2,4-二甲氧苯基丙酮
• 英文名称: 1-(2,4-dimethoxyphenyl)propan-2-one
• 英文别名: (2,4-dimethoxyphenyl)acetone；2',4'-dimethoxyphenylacetone；2,4-dimethoxy-phenylacetone；2,4-dimethoxyphenyl acetone；1-(2,4-dimethoxyphenyl)acetone；1-(2,4-Dimethoxy-phenyl)-propan-2-on
• CAS: 831-29-8
• 化学式: C₁₁H₁₄O₃
• mdl: MFCD00192065
• 分子量: 194.23
• InChiKey: LDUYRQGNBYKUAG-UHFFFAOYSA-N

物化性质

• 沸点：
  170-175 °C20 mm Hg(lit.)
• 密度：
  1.07 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  在常温常压下，该物质是稳定的。

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 海关编码：
  2914509090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : (2,4-Dimethoxyphenyl)acetone
CAS-No. : 831-29-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C11H14O3 C11H14O3
Molecular Weight : 194,23 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Normal measures for preventive fire protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection not required. For nuisance exposures use type OV/AG (US) or type ABEK
(EU EN 14387) respirator cartridges. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 170 - 175 °C at 27 hPa - lit.
boiling range
g) Flash point > 113,00 °C - closed cup
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,07 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  2,4-二甲氧基苯基丙酮 在 titanium(IV) isopropylate 、 氨 、 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 9.0h， 以87%的产率得到1-(2,4-二甲氧基苯基)丙-2-胺
  参考文献：
  名称：

  氨与羰基化合物的化学选择性还原烷基化：伯胺和对称仲胺的合成

  摘要：

  报道了一种高效的通用方法，用于用酮对氨进行高度化学选择性的还原性单烷基化。用乙醇和异丙醇钛（IV）中的氨处理酮，然后原位还原硼氢化钠，并直接进行后处理，得到的伯胺的收率好至极佳。另一方面，氨与醛的还原烷基化选择性地提供了相应的对称仲胺。

  DOI：

  10.1016/j.tet.2003.12.024
• 作为产物：
  描述：

  2,4-dimethoxybenzophenone 在 2-碘-5-甲基苯磺酸 作用下， 以 四氢呋喃 、 甲基叔丁基醚 、 水 、 异丙醇 为溶剂， 反应 4.42h， 生成 2,4-二甲氧基苯基丙酮
  参考文献：
  名称：

  以芳烃（碘）磺酸为前驱体，以丙酮为氧化剂，催化1,1'-双取代烯烃中的1,2-氧化转变

  摘要：

  描述了一种有效的催化高价碘介导的1,1'-二取代烯烃的氧化1,2-转变。该方法学提供了具有给电子取代基的均苄基酮的简明途径。在环状体系的情况下，这种转化导致环扩环的β-苯并环烷酮，这对于进一步完善是有用的。

  DOI：

  10.1021/ol400432x

文献信息

• Chemoselective reductive alkylation of ammonia with carbonyl compounds: synthesis of primary and symmetrical secondary amines
  作者：Bruhaspathy Miriyala、Sukanta Bhattacharyya、John S Williamson

  DOI：10.1016/j.tet.2003.12.024

  日期：2004.2

  efficient, general procedure for highly chemoselective reductive mono-alkylation of ammonia with ketones is reported. Treatment of ketones with ammonia in ethanol and titanium(IV) isopropoxide, followed by in situ sodium borohydride reduction, and a straightforward workup afforded primary amines in good to excellent yields. Reductive alkylation of ammonia with aldehydes, on the other hand, afforded the corresponding

  报道了一种高效的通用方法，用于用酮对氨进行高度化学选择性的还原性单烷基化。用乙醇和异丙醇钛（IV）中的氨处理酮，然后原位还原硼氢化钠，并直接进行后处理，得到的伯胺的收率好至极佳。另一方面，氨与醛的还原烷基化选择性地提供了相应的对称仲胺。
• Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  作者：Matthew J. Gaunt、Jinquan Yu、Jonathan B. Spencer

  DOI：10.1039/b103066n

  日期：——

  The allylic hydrogen is found to have a dramatic effect on the regioselectivity of the Wacker oxidation, leading to the postulation that an agostic hydrogen or enyl (σ + π) complex helps to stabilise the key intermediate.

  经发现，烯丙氢对Wacker氧化反应的区域选择性产生了显著影响，这导致了一种假设：即松散氢化合物或烯（σ + π）配合物有助于稳定关键中间体。
• Regioselective synthesis of 2-amino-isophthalonitriles through a ring transformation strategy
  作者：Fateh V. Singh、Vijay Kumar、Brijesh Kumar、Atul Goel

  DOI：10.1016/j.tet.2007.08.056

  日期：2007.11

  An expeditious synthesis of several 2-amino-isophthalonitriles and their biaryl compounds is described and illustrated by carbanion-induced ring transformation of functionalized 2H-pyran-2-ones with malononitrile in excellent yields. The strength of the reaction lies in the creation of an aromatic ring at room temperature from six-membered lactones under mild reaction conditions. This approach is an

  描述了几种2-氨基-间苯二甲腈及其联芳基化合物的快速合成方法，并通过羰基诱导的官能化的2 H-吡喃-2-酮与丙二腈的极高收率进行了环转化。反应的强度在于在室温下由六元内酯在温和的反应条件下产生芳环。该方法是2 H-吡喃-2-酮与亲二烯物的Diels-Alder反应的替代方法，后者需要强制加热条件才能获得苯衍生物。
• A novel route to arylacetones via a masked α-acylcarbonium intermediate
  作者：Shimon Shatzmiller、Ramy Lidor、Eytan Shalon、Elizer Bahar

  DOI：10.1039/c39840000795

  日期：——

  The Ag+ induced aromatic substitution reaction of bromoacetone O-methyloxime is described.

  描述了Ag +诱导的溴丙酮O-甲基肟的芳族取代反应。
• [EN] HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES HETERO BIARYLE INHIBITEURS DE LA METALLOPROTEASE MATRICIELLE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014366A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a' pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a' compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,,inflammatory bowel, disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically, acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active, component as described in the specification.

  该发明提供了由式I定义或其药用盐组成的化合物，其中R1、Q、S、T、U、V和R2如规范中所定义。该发明还提供了包括式I的化合物或其药用盐以及药用载体、稀释剂或赋形剂的药物组合物，如规范中所定义。该发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予式I的化合物或其药用盐。该发明还提供了治疗患有MMP-13酶介导疾病的患者的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、牛皮癣、动脉粥样硬化和骨质疏松症的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了组合物，包括式I的化合物或其药用盐，以及规范中描述的另一种药用活性成分。